Behrendt S, Wittchen H-U, Höfler M, Lieb R and Beesdo K (2009) Transitions from first substance use to substance use disorders in adolescence: is early onset associated with a rapid escalation?
Drug and Alcohol Dependence
Brunt TM, van Laar M, Niesink RJ and van den Brink W (2010) The relationship of quality and price of the psychostimulants cocaine and amphetamine with health care outcomes. Drug and Alcohol Dependence
Cascini F, Aiello C and Di Tanna G (2012) Increasing delta-9-tetrahydrocannabinol (Δ−9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Current Drug Abuse Reviews
Chan GC, Hall W, Freeman TP, Ferris J, Kelly AB and Winstock A (2017) User characteristics and effect profile of Butane Hash Oil: an extremely high-potency cannabis concentrate. Drug and Alcohol Dependence
Colizzi M and Bhattacharyya S (2017) Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Current Addiction Reports
Courtney KE, Mejia MH and Jacobus J (2017) Longitudinal studies on the etiology of cannabis use disorder: a review. Current Addiction Reports
Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ and Parsons LH (2016) Keep off the grass? Cannabis, cognition and addiction. Nature Reviews Neuroscience
Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M
et al. (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The Lancet Psychiatry
D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T
et al. (2008) Blunted psychotomimetic and amnestic effects of Δ−9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology
ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S and Church JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biological Psychiatry
EMCDDA (2014) Report to the EMCDDA by the Reitox National Focal Point. The Netherlands Drug Situation 2014. Luxembourg: Publications Office of the European Union.
EMCDDA (2016) European Drug Report: Trends and Developments. Luxembourg: Publications Office of the European Union.
Englund A, Freeman TP, Murray RM and McGuire P (2017) Can we make cannabis safer?
The Lancet Psychiatry
Freeman T and Winstock A (2015) Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychological Medicine
Freeman TP, Morgan CJA, Hindocha C, Schafer GL, Das RK and Curran HV (2014) Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints?
Freeman TP and Swift W (2016) Cannabis potency: the need for global monitoring. Addiction
McLaren J, Swift W, Dillon P and Allsop S (2008) Cannabis potency and contamination: a review of the literature. Addiction
Meier MH (2017) Associations between butane hash oil use and cannabis-related problems. Drug and Alcohol Dependence
Mokrysz C, Freeman T, Korkki S, Griffiths K and Curran H (2016) Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Translational Psychiatry
Monaghan M, Hamilton I, Lloyd C and Paton K (2016) Cannabis matters? Treatment responses to increasing cannabis presentations in addiction services in England. Drugs: Education, Prevention and Policy
Monshouwer K, Van Laar M and Vollebergh WA (2011) Buying cannabis in ‘coffee shops’. Drug and Alcohol Review
Montanari L, Guarita B, Mounteney J, Zipfel N and Simon R (2017) Cannabis use among people entering drug treatment in Europe: a growing phenomenon?
European Addiction Research
NDTMS (2014) Adult Drug Statistics from the National Drug Treatment Monitoring System (NDTMS).
Nguyen H and Reuter P (2012) How risky is marijuana possession? Considering the role of age, race, and gender. Crime & Delinquency
Niesink RJ, Rigter S, Koeter MW and Brunt TM (2015) Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15. Addiction
Pijlman F, Rigter S, Hoek J, Goldschmidt H and Niesink R (2005) Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addiction Biology
Potter DJ, Clark P and Brown MB (2008) Potency of Δ9–THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. Journal of Forensic Sciences
Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O
et al. (2016) Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. The Lancet Psychiatry
Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS and Boks MP (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Research
Sevigny EL (2013) Is today's marijuana more potent simply because it's fresher?
Drug Testing and Analysis
Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM
et al. (2014) Young adult sequelae of adolescent cannabis use: an integrative analysis. The Lancet Psychiatry
Smart R, Caulkins JP, Kilmer B, Davenport S and Midgette G (2017) Variation in cannabis potency and prices in a newly-legal market: evidence from 30 million cannabis sales in Washington state. Addiction
Swift W, Wong A, Li KM, Arnold JC and McGregor IS (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS ONE
UNODC (2016) United Nations Office on Drugs and Crime, World Drug Report 2016 (United Nations publication, Sales No. E.16.XI.7).
van der Pol P, Liebregts N, Brunt T, Amsterdam J, Graaf R, Korf DJ
et al. (2014) Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction
van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W and van Laar M (2013a) Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug and Alcohol Dependence
van der Pol P, Liebregts N, Graaf R, Have M, Korf DJ, Brink W
et al. (2013b) Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction
Van Laar M, Van Der Pol P and Niesink R (2016) Limitations to the Dutch cannabis toleration policy: assumptions underlying the reclassification of cannabis above 15% THC. International Journal of Drug Policy
Wisselink DJ, Kuijpers WGT and Mol A (2016) Key Figures Addiction Care 2015. Houten: Stichting Informatie Voorziening Zorg.
Wouters M and Korf DJ (2009) Access to licensed cannabis supply and the separation of markets policy in the Netherlands. Journal of Drug Issues